The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for Merck and Ridgeback Therapeutics’ molnupiravir (to be trademarked LAGEVRIO in the UK). Results from an interim analysis from the Phase III MOVe-OUT clinical trial showed that the oral treatment could halve the risk of hospitalization or death for adults with a positive SARS-CoV-2 diagnostic test and mild to moderate COVID symptoms and who had at least one risk factor have at least one risk factor for developing severe illness.
The approval is ”a major achievement in Merck’s singular legacy of bringing forward breakthrough medicines and vaccines to address the world’s greatest health challenges,“ said Robert M. Davis, the company’s chief executive officer and president.
Wendy Holman, chief executive officer of Ridgeback Biotherapeutics, commented: ”It is also gratifying to see the first global authorization occur in the UK, the very place where we administered molnupiravir to the first brave human volunteer.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.